Claims for Patent: 7,582,297

Summary for Patent: 7,582,297

Title:	Methods of treating respiratory conditions
Abstract:	The present invention provides prophylactic an tehrapeutic protocols desinged to prevent, manage, treat, or ameliorate a respiratory condition or one or more symptoms thereof. In particular, the present invention provides methods for preventing, managinge, treating, or ameliorating a respiratory condition or one or symptoms caused by environmental factors or a respiratory infection. The present ivnention encompasses combination therapies, pharamceutical compositions, articles of manufacture, and kits.
Inventor(s):	Reed; Jennifer Lynne (Clarksburg, MD)
Assignee:	MedImmune, LLC (Gaithersburg, MD)
Application Number:	10/823,810
Patent Claims:	1. A method of treating or ameliorating a respiratory infection, or a symptom thereof, in a human subject suffering therefrom, said method comprising administering to said human subject an effective amount of an antibody or fragment thereof that immunospecifically binds IL-9, wherein the antibody or fragment thereof comprises: (a) a VH CDR1 comprising the amino acid sequence of SEQ ID NO:26, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:64, a VH CDR3 comprising the amino acid sequence of SEQ NO:3, a VL CDR1 comprising the amino acid sequence of SEQ ID NO:65, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:66, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:20; or (b) a VH domain comprising the amino acid sequence of SEQ ID NO:27 and a VL domain comprising the amino acid sequence of SEQ ID NO:28. 2. A method of treating or ameliorating wheezing in a human pre-term infant, a human infant or a human child, said method comprising administering to said pre-term infant, infant or child an effective amount of an antibody or fragment thereof that immunospecifically binds IL-9, wherein the antibody or fragment thereof comprises: (a) a VH CDR1 comprising the amino acid sequence of SEQ ID NO:26, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:64, a VH CDR3 comprising the amino acid sequence of SEQ ID NO:3, a VL CDR1 comprising the amino acid sequence of SEQ ID NO:65, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:66, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:20; or (b) a VH domain comprising the amino acid sequence of SEQ ID NO:27 and a VL domain comprising the amino acid sequence of SEQ ID NO:28. 3. A method of treating or ameliorating wheezing in a human subject suffering therefrom, said method comprising administering to said human subject: an effective amount of an antibody or fragment thereof that immunospecifically binds IL-9, wherein the antibody or fragment thereof comprises: (a) a VH CDR1 comprising the amino acid sequence of SEQ ID NO:26, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:64, a VH CDR3 comprising the amino acid sequence of SEQ ID NO:3, a VL CDR1 comprising the amino acid sequence of SEQ ID NO:65, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:66, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:20; or (b) a VH domain comprising the amino acid sequence of SEQ ID NO:27 and a VL domain comprising the amino acid sequence of SEQ ID NO:28, and an effective amount of at least one other therapy that is not administration of an IL-9 antagonist. 4. A method of treating or ameliorating asthma or an allergy, or one or more symptoms thereof, in a human subject suffering therefrom, said method comprising administering to said human subject: an effective amount of an antibody or fragment thereof that immunospecifically binds IL-9, wherein the antibody or fragment thereof comprises: (a) a VH CDR1 comprising the amino acid sequence of SEQ ID NO:26, a VH CDR2 comprising the amino acid sequence of SEQ ID NO:64, a VH CDR3 comprising the amino acid sequence of SEQ ID NO:3, a VL CDR1 comprising the amino acid sequence of SEQ ID NO:65, a VL CDR2 comprising the amino acid sequence of SEQ ID NO:66, and a VL CDR3 comprising the amino acid sequence of SEQ ID NO:20; or (b) a VH domain comprising the amino acid sequence of SEQ ID NO:27 and a VL domain comprising the amino acid sequence of SEQ ID NO:28, and an effective amount of at least one other asthma or allergy therapy. 5. The method of claim 1 or 2 further comprising administering an effective amount of at least one other therapy that is not administration of an IL-9 antagonist. 6. The method of claim 1, wherein the respiratory infection is a viral infection, a bacterial infection or a fungal infection. 7. The method of claim 6, wherein the viral infection is a parainfluenza virus infection, an influenza virus infection or a metapneumovirus infection. 8. The method of claim 6, wherein the viral infection is a respiratory syncytial virus (RSV) infection. 9. The method of claim 5, wherein the therapy is an immunomodulatory agent, an anti-inflammatory agent, an anti-viral agent, an antibiotic, an antifungal agent or a mast cell modulator. 10. The method of claim 8, further comprising administering to said subject an effective amount of an anti-RSV antigen antibody. 11. The method of claim 10, wherein the anti-RSV antigen antibody is palivizumab. 12. The method of claim 1 or 2 further comprising administering a leukotriene modifier. 13. The method of claim 12, wherein the leukotriene modifier is montelukast, zafirlukast, pranlukast or zileuton. 14. The method of claim 3 or 4, wherein the therapy is an immunomodulatory agent, an anti-inflammatory agent, an anti-viral agent, an antibiotic, an antifungal agent or a mast cell modulator. 15. The method of claim 3 or 4 further comprising administering to said subject a leukotriene modifier, an anti-histamine, an anti-IgE antibody, an anti-IL-4 antibody or a mast cell protease inhibitor. 16. The method of claim 10 further comprising administering a leukotriene modifier. 17. The method of claim 2, 3 or 4 , wherein the antibody or fragment thereof is administered parenterally, orally or intranasally. 18. The method of claim 1, wherein the subject is a pre-term infant, an infant, a child or an elderly person. 19. The method of claim 1, wherein the subject has bronchopulmonary dysplasia, congenital heart disease, cystic fibrosis or acquired or congenital immunodeficiency. 20. The method of claim 3 or 4, wherein the subject is a pre-term infant, an infant, a child or an elderly person. 21. The method of claim 3 or 4, wherein the subject has bronchopulmonary dysplasia, congenital heart disease, cystic fibrosis or acquired or congenital immunodeficiency. 22. The method of claim 1 wherein the antibody or fragment thereof is administered parenteraily, orally or intranasally.

Details for Patent 7,582,297

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Swedish Orphan Biovitrum Ab (publ)	SYNAGIS	palivizumab	For Injection	103770	06/19/1998		2023-04-11
Swedish Orphan Biovitrum Ab (publ)	SYNAGIS	palivizumab	Injection	103770	07/23/2004		2023-04-11
Jubilant Hollisterstier Llc	N/A	positive skin test control-histamine	Injection	103891	03/13/1924		2023-04-11